We are working on a monocyte-based immunotherapy, comparable to CAR T-cell therapies, for immunological cold, solid tumors. In detail, we are gene-engineering monocytes, which will migrate into the tumor, differentiate there to macrophages and because of our modifications, they will attack the tumor and cause an inflammation. That will break up the immune suppressive tumor microenvironment and trigger tumor specific immune responses.
The lead indication is triple negative breast cancer (TNBC), it affects more young women than other breast cancer types, has the worst prognosis and there is a high unmet need for better therapies. If we can show that we are successful in treating TNBC we would scale our technology to other indications such as pancreas, ovary and prostate cancer.
